Cybin Inc., a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects its common shares to cease trading on NYSE American at market close on Jan. 4, 2026, and to begin trading on Nasdaq at market open on Jan. 5, 2026, at which time the ticker symbol will change from "CYBN" to "HELP." Cybin will remain listed on Cboe Canada and will also trade under the "HELP" ticker on that exchange beginning Jan. 5, 2026.
This transfer represents a significant strategic move for Cybin as it advances its clinical programs targeting major mental health conditions. The company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, with additional research pipeline compounds focused on 5-HT-receptors.
The listing transfer to Nasdaq, a premier exchange for growth companies, particularly in the biotechnology and pharmaceutical sectors, provides Cybin with enhanced visibility among institutional investors and analysts who specialize in healthcare innovation. Nasdaq's reputation as a hub for innovative companies could potentially increase trading liquidity and analyst coverage for Cybin as it progresses through late-stage clinical trials. The ticker symbol change to "HELP" directly aligns with the company's mission of addressing the large unmet need for people who suffer from mental health conditions.
For investors, this development signals Cybin's maturation as a clinical-stage company with advanced programs approaching potential regulatory milestones. The timing of the transfer coincides with the company's progression of CYB003 through Phase 3 studies, suggesting strategic alignment of corporate development with clinical advancement. Investors can access the latest news and updates relating to Cybin in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the listing transfer is available at https://ibn.fm/pcrpA.
The mental healthcare sector faces significant challenges with many existing treatments providing inadequate relief for patients suffering from conditions like major depressive disorder and generalized anxiety disorder. Cybin's approach to developing novel psychedelic-inspired compounds represents a potential paradigm shift in neuropsychiatry. As the company advances its clinical programs, the Nasdaq listing provides a platform that may better reflect its growth trajectory and the transformative potential of its research. This move occurs as regulatory frameworks for psychedelic-based therapies continue to evolve, creating both opportunities and challenges for companies operating in this emerging treatment space.
